Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, L., Small molecule-based Lifespan extension therapy: Exendin-4/Exenatide, a Glucagon-Like Protein-1 (GLP-1) Receptor Agonist, may prolong mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 13/April/2014, 11.14 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Significance: It has been shown earlier that angiotensin II type I receptor (AT1R) antagonist prolongs mammalian life span. Exendin-4/Exenatide is used in the treatment of diabetes mellitus type 2 (T2DM). This study suggests, for the first time, that Exendin-4, by increasing the expression of its target gene, it may suppress the expression of AT1R. And, thereby, it may (1) decrease blood pressure; and (2) and extend the lifespan of an individual. Thus, pharmacological formulations encompassing “Exendin-4 or its analogues“ may be used to extend the life-span of an individual.
Undisclosed information: How Exendin-4 suppresses the expression of angiotensin II type I receptor (AT1R)
